PRIMARY EVANS SYNDROME (ES)

Clinical trials for PRIMARY EVANS SYNDROME (ES) explained in plain language.

Never miss a new study

Get alerted when new PRIMARY EVANS SYNDROME (ES) trials appear

Sign up with your email to follow new studies for PRIMARY EVANS SYNDROME (ES), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New combo therapy aims to control stubborn blood disorder

Disease control Not yet recruiting

This study is testing whether adding a new drug called ianalumab to standard platelet-boosting medications is safe and tolerable for adults with primary immune thrombocytopenia (ITP). Researchers want to see if this combination helps improve platelet counts and allows patients to…

Matched conditions: PRIMARY EVANS SYNDROME (ES)

Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Mar 16, 2026 15:24 UTC

PRIMARY EVANS SYNDROME (ES)

Get alerted when new PRIMARY EVANS SYNDROME (ES) trials appear

New combo therapy aims to control stubborn blood disorder